Lupus Nephritis Market Summary
According to DelveInsight’s analysis, the Lupus nephritis market size was found to be nearly USD 2,130 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025, and it is projected to reach nearly USD 4,510 million by 2036, growing at a CAGR of approximately 7% during 2026–2036. Lupus nephritis is one of the most serious complications of systemic lupus erythematosus (SLE), affecting approximately 40-60% of SLE patients, with 10-30% of those advancing to end-stage renal disease (ESRD) despite therapy. Among the histological subtypes, Class IV remains the most prevalent and carries the worst prognosis, while Classes I and II are associated with milder disease. Growing physician confidence in newly approved targeted therapies, along with substantial investment in CAR-T approaches, is expected to reshape the treatment landscape through the forecast period.
Explore DelveInsight’s Full Coverage on the Lupus Nephritis Market
Lupus Nephritis Overview and Diagnosis
Lupus nephritis is one of the most serious organ manifestations of SLE, arising when autoimmune-mediated injury targets the kidneys and disrupts normal renal function. The disease exhibits a highly variable clinical course, ranging from asymptomatic urinary abnormalities to progressive renal impairment. Common manifestations include proteinuria, hematuria, hypertension, edema, and declining kidney function. Lupus nephritis is categorized into six histological classes (I–VI), reflecting distinct patterns of renal involvement that influence prognosis and management. Diagnosis requires a comprehensive assessment of clinical presentation, laboratory findings, and renal function, with urine and blood tests serving as key initial evaluations. Kidney biopsy remains the cornerstone of diagnosis, providing essential information on disease classification, activity, and chronicity.
Lupus Nephritis Treatment Landscape
Management of lupus nephritis is guided by disease class, severity of renal involvement, and risk of disease progression, with the primary goals of controlling inflammation, preserving kidney function, and preventing progression to chronic kidney disease (CKD) or ESRD. Patients with milder Class I and II disease may require close monitoring, while Classes III, IV, and V typically necessitate intensive treatment with corticosteroids and immunosuppressive agents. Supportive therapies, including ACE inhibitors or ARBs for proteinuria and hypertension, and lipid-lowering agents, remain important components of care. In recent years, the treatment landscape has expanded beyond conventional immunosuppression with the approval of targeted therapies such as belimumab, voclosporin, and obinutuzumab. Despite these advances, many patients continue to experience relapses, incomplete responses, or progressive kidney damage.
Lupus Nephritis Market Players
Lupus Nephritis companies include:
- GlaxoSmithKline
- Aurinia Pharmaceuticals
- Otsuka Pharmaceuticals
- Roche
- AstraZeneca
- Novartis
- MorphoSys
- Idorsia Pharmaceuticals
- Viatris
- Autolus
- Kyverna Therapeutics
- Cabaletta Bio
- And others.
Lupus Nephritis Epidemiology
The epidemiology section of the Lupus nephritis market insight report provides historical and forecasted data segmented by Total Diagnosed Prevalent Cases, Age-specific Diagnosed Prevalent Cases, Diagnosed Prevalent Cases by Class, and Total Treated Cases across the 7MM covering the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2022 to 2036.
Key Findings:
- The total Diagnosed Prevalent Cases of Lupus Nephritis in the US comprised nearly 211,800 cases in 2025 and are projected to increase during the forecast period
- In 2025, Spain held the largest lupus nephritis market share within the EU4 and the UK, accounting for approximately 34% of the combined market, reflecting a notably higher disease prevalence rate than other EU4 countries, the UK, Japan, and the US
- In 2025, diagnosed prevalent cases of lupus nephritis in the US were distributed as approximately 7% in individuals aged under 18 years and around 93% in those aged 18 years and older
- In Japan, Class IV was the most prevalent form of lupus nephritis in 2025, with around 18,000 diagnosed cases, followed by Class III with around 6,800 reported cases
Lupus Nephritis Market Outlook
The lupus nephritis treatment landscape has evolved significantly with the introduction of targeted therapies alongside conventional immunosuppressive regimens, with treatment generally divided into induction and maintenance phases. Mycophenolate mofetil (MMF), cyclophosphamide, and corticosteroids continue to form the backbone of therapy, while belimumab, voclosporin, and the recently approved obinutuzumab have expanded treatment options. Clinical practice increasingly favors combination approaches, particularly for Class III/IV and Class V disease. The addition of voclosporin and belimumab to American College of Rheumatology and KDIGO 2024 guideline updates reflects a growing preference for combination therapies. Increasing awareness, earlier detection of renal involvement, and expanding use of targeted therapies are expected to drive steady market growth across the 7MM through 2036, with emerging immunomodulatory therapies further reshaping the landscape.
Marketed Lupus Nephritis Drugs
Voclosporin (LUPKYNIS) – Aurinia Pharmaceuticals/Otsuka Pharmaceuticals
Voclosporin is a novel, structurally modified calcineurin inhibitor with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production while promoting podocyte stability in the kidney. It reduces cytokine activation by inhibiting calcineurin and blocks IL-2 expression and T-cell-mediated immune responses.
- Approved by the FDA in January 2021 for active lupus nephritis alongside standard immunosuppressive therapy, as the first oral medication specifically approved for the indication
- EU approval followed in 2022, and Japan approval in 2024
Belimumab (BENLYSTA) – GlaxoSmithKline
Belimumab is a human monoclonal antibody that inhibits BLyS, reducing the survival of autoreactive B cells and autoantibody production in lupus. It is indicated as an add-on therapy for patients aged 5 years and older with active SLE and lupus nephritis, administered via intravenous infusion or subcutaneous injection.
- Approved for lupus nephritis in the US in 2020 for adults and in 2022 for pediatric patients
- Approved in the EU and Japan in 2021, as the first and only biologic approved for both SLE and lupus nephritis
Obinutuzumab (GAZYVA/GAZYVARO) – Genentech (Roche)
Obinutuzumab is an anti-CD20 monoclonal antibody administered via IV infusion for adults with active lupus nephritis, approved in both the US and EU in 2025, further expanding biologic treatment options for patients with active disease.
Emerging Lupus Nephritis Drugs
The Lupus nephritis pipeline is led by drug classes including complement inhibitors (iptacopan), BAFF-R antagonists (ianalumab), monoclonal antibodies (anifrolumab), Sphingosine-1-phosphate 1 receptor modulators (cenerimod), and CAR-T therapies (resecabtagene autoleucel, rapcabtagene autoleucel, obecabtagene autoleucel, C-CAR168, mivocabtagene autoleucel), among others.
Anifrolumab (SAPHNELO) – AstraZeneca
Anifrolumab is an intravenously administered, fully human monoclonal antibody that binds to Subunit 1 of the Type I IFN receptor, blocking Type I IFN activity and STAT1 phosphorylation. The drug is currently being evaluated in the Phase III IRIS trial for adult subjects with active proliferative lupus nephritis.
Ianalumab (VAY736) – Novartis/MorphoSys
Ianalumab is a fully human monoclonal antibody targeting B cells through both antibody-dependent cellular toxicity (ADCC) and interruption of BAFF-R mediated signaling, currently in Phase III development for lupus nephritis. Per Novartis’s 2026 interim financial report, Phase III readouts are anticipated by 2027, with regulatory submission for lupus nephritis expected in 2028.
Cenerimod – Idorsia Pharmaceuticals/Viatris
Cenerimod is an oral small-molecule sphingosine 1-phosphate receptor modulator in Phase III development. Per the company’s Q4 2025 results (February 2026), the Phase III trial is currently enrolling patients, with enrollment completion targeted for the first half of 2028.
Rapcabtagene autoleucel (YTB323) – Novartis
Rapcabtagene autoleucel is a CD19-targeted autologous CAR T-cell therapy administered via IV infusion, currently in Phase II development for SLE and lupus nephritis.
Lupus Nephritis Drugs Uptake
Cabaletta Bio plans to leverage its FDA alignment in myositis during the third quarter of 2025 to finalize a registrational clinical design for SLE/lupus nephritis, with plans to present full Phase I/II data and begin enrollment in registrational cohorts by the first half of 2026. All CAR-T therapies in development – C-CAR168, resecabtagene autoleucel, rapcabtagene autoleucel, and obecabtagene autoleucel – show promise for treating lupus nephritis, though it remains too early to determine which will prove superior, with larger, longer-term trials needed to confirm efficacy and safety.
Download the Lupus Nephritis market report for in-depth insights on pipeline and forecast
Conclusion
The Lupus nephritis market is positioned for steady growth through 2036, driven by rising disease prevalence, earlier detection of renal involvement, and expanding adoption of targeted therapies beyond conventional immunosuppression. While belimumab, voclosporin, and obinutuzumab are expected to remain key market drivers in the near term, an active pipeline spanning complement inhibitors, BAFF-R antagonists, interferon receptor antagonists, and CAR-T cell therapies signals a promising shift toward more personalized and durable disease management. Despite these advances, unmet needs around biomarker gaps, quality of life, and long-term disease control persist, underscoring continued opportunity for innovation as the treatment landscape evolves over the coming decade.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
